.jpg?format=webp&width=780)
Assess costs, health care resource utilization, and treatment‐taking behaviour (persistence and adherence) to OAB medication in older, frail OAB patients. From 2527 patients with incident mirabegron (21%) or antimuscarinic (79%) dispensations, 516 incident mirabegron users (median age: 82 years, 64% female) were matched to 1032 incident antimuscarinic users (median age: 81 years, 62% female). Among frail older adults with OAB, mirabegron use was associated with higher costs and potential improvements in treatment‐taking behaviours, particularly concerning treatment adherence, versus those initiating antimuscarinics.
Like
Save
Share